Search results
Showing 1336 to 1350 of 1519 results for do not do recommendations
This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.
View quality statements for QS104Show all sections
Sections for QS104
- Quality statements
- Quality statement 1: Acute cholecystitis
- Quality statement 2: Urgent endoscopic retrograde cholangiopancreatography within 72 hours
- Quality statement 3: Emergency endoscopic retrograde cholangiopancreatography within 24 hours
- Quality statement 4: Advice to prevent symptoms
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of ...
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin...
View recommendations for HTE24Show all sections
Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes